{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:59:30Z","timestamp":1777535970598,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmorw.2024.100063","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:38:29Z","timestamp":1726727909000},"page":"100063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["EBANO study: real-world data from patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC) in Northern Spain"],"prefix":"10.1016","volume":"6","author":[{"given":"R.","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sagastibeltza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pujol Obis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lainez Milagro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"S\u00e1nchez-Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mart\u00ednez Kareaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Verd\u00fan Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arruti Ibarbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pumares Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"de Portugal Fern\u00e1ndez del Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lacalle Emborujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gil Arnaiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pereira-Elorrieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"\u00c1lvarez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmorw.2024.100063_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A\u00a0consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100063_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ije\/dyw044","article-title":"Quantified relations between exposure to tobacco smoking and bladder cancer risk: meta-analysis of 89 observational studies","volume":"45","author":"van Osch","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100063_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmorw.2024.100063_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2015.11.006","article-title":"Perioperative treatment and radical cystectomy for bladder cancer\u2014a population based trend analysis of 10,338 patients in the Netherlands","volume":"54","author":"Hermans","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6 Pt 1","key":"10.1016\/j.esmorw.2024.100063_bib10","first-page":"2414","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.esmorw.2024.100063_bib11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100063_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","article-title":"Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma","volume":"5","author":"Kamat","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10122","key":"10.1016\/j.esmorw.2024.100063_bib13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase III randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"10031","key":"10.1016\/j.esmorw.2024.100063_bib16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmorw.2024.100063_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2024.100063_bib20","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100063_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100063_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.esmorw.2024.100063_bib24","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1002\/cncr.24460","article-title":"Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study","volume":"115","author":"Vaughn","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.esmorw.2024.100063_bib25","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A\u00a0primer on effectiveness and efficacy trials","volume":"5","author":"Singal","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.esmorw.2024.100063_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BLC-150018","article-title":"The role of population-based observational research in bladder cancer","volume":"1","author":"Robinson","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.esmorw.2024.100063_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.hoc.2021.01.005","article-title":"Real world outcomes of patients with bladder cancer effectiveness versus efficacy of modern treatment paradigms","volume":"35","author":"Pfail","year":"2021","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100063_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Witjes","year":"2017","journal-title":"Eur Urol"},{"issue":"suppl 3","key":"10.1016\/j.esmorw.2024.100063_bib29","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100063_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","article-title":"Urothelial carcinoma management in elderly or unfit patients","volume":"14","author":"Bellmunt","year":"2016","journal-title":"EJC Suppl"},{"issue":"21","key":"10.1016\/j.esmorw.2024.100063_bib31","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2024.100063_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2024.100063_bib33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T08:05:39Z","timestamp":1734163539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S2949820124000419"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100063","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EBANO study: real-world data from patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC) in Northern Spain","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100063"}}